The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes
Explore this paper's citation graph
Summary
Basal-like and HER2+/ER− subtypes are more sensitive to anthracycline-based neoadjuvant chemotherapy than luminal breast cancers and could be explained by a higher likelihood of relapse in patients in whom pathologic complete response was not achieved.
- Type
- article
- Published
- 2007-04-15
- Cited by
- 2,082
- References
- 23
- Access
- Open access
- OpenAlex
- https://openalex.org/W2157285286
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:6549591
Keywords
Breast cancer, Anthracycline, Internal medicine, Estrogen receptor, Chemotherapy
References
- [New guidelines to evaluate the response to treatment in solid tumors].
- Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy.
- Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma
- Concordance among gene-expression-based predictors for breast cancer.
- Molecular portraits of human breast tumours
- Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma
- Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer.
- Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer.
- Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
- Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy.
- New guidelines to evaluate the response to treatment in solid tumors
- Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.
- Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.
- Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.
- American Joint Committee on Cancer tumor-node-metastasis stage after neoadjuvant chemotherapy and breast cancer outcome.
- Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy
- Repeated observation of breast tumor subtypes in independent gene expression data sets
- Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
- Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.
- Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer.
Cited by
- [Identification of basal-like carcinomas in clinical practice: "triple zero/BRCA1-like" carcinomas].
- Phosphorylated mTOR expression correlates with poor outcome in early-stage triple negative breast carcinomas.
- Comparing Genetically Engineered Mouse Mammary Cancer Models with Human Breast Cancer by Expression Profiling
- Triple-negative breast cancers express receptors for luteinizing hormone-releasing hormone (LHRH) and respond to LHRH antagonist cetrorelix with growth inhibition.
- Worse prognosis of metaplastic breast cancer patients than other patients with triple-negative breast cancer
- What Is the Difference Between Triple-Negative and Basal Breast Cancers?
- Systemic treatment of early breast cancer—a biological perspective
- Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer
- Sensitization of BCL-2–expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737
- Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience.
- Prevention of ER-negative breast cancer: where do we stand?
- Evaluation of tumor extent in breast cancer patients using real-time MR navigated ultrasound: preliminary study.
- Immunohistochemistry-based subtyping of breast carcinoma in Egyptian women: a clinicopathologic study on 125 patients.
- ALK alteration is a frequent event in aggressive breast cancers
- Association of Pathologic Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer With Long-Term Outcomes: A Meta-Analysis.
- Diagnostic Performance of MRI for Assessing Tumor Response in HER2 Negative Breast Cancer Receiving Neoadjuvant Chemotherapy Is Associated with Molecular Biomarker Profile
- The apoptotic members CD95, BclxL, and Bcl-2 cooperate to promote cell migration by inducing Ca2+ flux from the endoplasmic reticulum to mitochondria
- Younger age is an independent predictor of worse prognosis among Lebanese nonmetastatic breast cancer patients: analysis of a prospective cohort
- How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies
- Avelumab, an IgG1 anti-PD-L1 Immune Checkpoint Inhibitor, Triggers NK Cell-Mediated Cytotoxicity and Cytokine Production Against Triple Negative Breast Cancer Cells
Related papers
- Follow-up Study of Children with Anthracycline Cardiotoxicity
- Expression of TopoisomeraseII(TopoIIα) in Human Breast Carcinoma Tissues and its Relationship with Anthracycline Sensitivity
- Clinical implications of HER-2 and P53 in taxane-based and anthracycline-based neoadjuvant chemotherapy in breast cancer
- HER-2 and topoisomerase II as predictors of response to chemotherapy.
- Association of BRCAness with taxane resistance in triple-negative breast cancer: A study of 7 cases
- Biological markers as predictive factors of response to neoadjuvant taxanes and anthracycline chemotherapy in breast carcinoma
- NOLUS: a predictive model to identify Basal-like and HER2-enriched intrinsic subtypes based on estrogen receptor (ER), progesterone receptor (PR) and Ki67 immunohistochemistry (IHC) in hormone receptor-positive/HER2-negative (HR+/HER2–) breast cancer (BC)
- Correlation of meningioma hormone receptor status with hormone sensitivity in a tumor stem-cell assay.
- Hormone Receptor Status in Breast Cancer and its Relation to Age and Other Prognostic Factors
- Hormone‐dependent processing of the avian progesterone receptor